NASDAQ: FGEN
Fibrogen Inc Stock Forecast, Predictions & Price Target

Analyst price target for FGEN

Based on 1 analyst offering 12 month price targets for Fibrogen Inc

Min Forecast
$10.00+3,384.32%
Avg Forecast
$10.00+3,384.32%
Max Forecast
$10.00+3,384.32%

Should I buy or sell FGEN stock?

Based on 1 analyst offering ratings for Fibrogen Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their FGEN stock forecasts and price targets.

FGEN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-18

1 of 1

Forecast return on equity

Is FGEN forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is FGEN forecast to generate an efficient return on assets?

Company
-20.7%
Industry
36.07%
FGEN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

FGEN earnings per share forecast

What is FGEN's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$0.60
Avg 2 year Forecast
-$0.78
Avg 3 year Forecast
-$0.58

FGEN revenue forecast

What is FGEN's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$6.0M-79.74%
Avg 2 year Forecast
$7.0M-76.37%
Avg 3 year Forecast
$121.4M+309.68%
FGEN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

FGEN revenue growth forecast

How is FGEN forecast to perform vs Biotechnology companies and vs the US market?

Company
51.23%
Industry
65.48%
Market
10.37%
FGEN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
FGEN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

FGEN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
FGEN$0.29$10.00+3,384.32%Buy
INKT$7.26$19.50+168.60%Buy
BRNS$0.71$3.00+322.54%Buy
ALLK$0.33N/AN/A
INTS$1.94$6.75+247.94%Strong Buy

Fibrogen Stock Forecast FAQ

Is Fibrogen Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: FGEN) stock is to Buy FGEN stock.

Out of 1 analyst, 0 (0%) are recommending FGEN as a Strong Buy, 1 (100%) are recommending FGEN as a Buy, 0 (0%) are recommending FGEN as a Hold, 0 (0%) are recommending FGEN as a Sell, and 0 (0%) are recommending FGEN as a Strong Sell.

If you're new to stock investing, here's how to buy Fibrogen stock.

What is FGEN's earnings growth forecast for 2025-2027?

(NASDAQ: FGEN) Fibrogen's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.

Fibrogen's earnings in 2025 is -$47,579,000.On average, 2 Wall Street analysts forecast FGEN's earnings for 2025 to be -$60,045,589, with the lowest FGEN earnings forecast at -$88,806,921, and the highest FGEN earnings forecast at -$31,284,256. On average, 2 Wall Street analysts forecast FGEN's earnings for 2026 to be -$78,210,641, with the lowest FGEN earnings forecast at -$86,788,582, and the highest FGEN earnings forecast at -$69,632,700.

In 2027, FGEN is forecast to generate -$58,531,834 in earnings, with the lowest earnings forecast at -$72,660,208 and the highest earnings forecast at -$44,403,461.

What is FGEN's revenue growth forecast for 2025-2027?

(NASDAQ: FGEN) Fibrogen's forecast annual revenue growth rate of 51.23% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.37%.

Fibrogen's revenue in 2025 is $29,621,000.On average, 2 Wall Street analysts forecast FGEN's revenue for 2025 to be $605,501,736, with the lowest FGEN revenue forecast at $605,501,736, and the highest FGEN revenue forecast at $605,501,736. On average, 2 Wall Street analysts forecast FGEN's revenue for 2026 to be $706,418,692, with the lowest FGEN revenue forecast at $605,501,736, and the highest FGEN revenue forecast at $807,335,648.

In 2027, FGEN is forecast to generate $12,246,272,611 in revenue, with the lowest revenue forecast at $605,501,736 and the highest revenue forecast at $23,887,043,485.

What is FGEN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: FGEN) forecast ROA is -20.7%, which is lower than the forecast US Biotechnology industry average of 36.07%.

What is FGEN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year FGEN price target, the average FGEN price target is $10.00, with the highest FGEN stock price forecast at $10.00 and the lowest FGEN stock price forecast at $10.00.

The Wall Street analyst predicted that Fibrogen's share price could reach $10.00 by Mar 18, 2026. The average Fibrogen stock price prediction forecasts a potential upside of 3,384.32% from the current FGEN share price of $0.29.

What is FGEN's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: FGEN) Fibrogen's current Earnings Per Share (EPS) is -$0.48. On average, analysts forecast that FGEN's EPS will be -$0.60 for 2025, with the lowest EPS forecast at -$0.88, and the highest EPS forecast at -$0.31. On average, analysts forecast that FGEN's EPS will be -$0.78 for 2026, with the lowest EPS forecast at -$0.86, and the highest EPS forecast at -$0.69. In 2027, FGEN's EPS is forecast to hit -$0.58 (min: -$0.72, max: -$0.44).

What is FGEN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: FGEN) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.